CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic. Methods: CR3022 was labeled with 131 I and purified, yielding 131 I-CR3022. Using a magnetic bead assay and a recombinant SARS-CoV-2 spike protein fragment, we tested binding of 131 I-CR3022 in the presence and absence of CR3022. Results: We conjugated the antibody CR3022 with a purity of more than 98% and a specific activity of more than 292 MBq/mg. Using a bead-based assay, we confirmed that binding of 131 I-CR3022 is selective and is significantly reduced in the presence of unlabeled antibody (3.14% ± 0.14% specific uptake and 0.10% ± 0.01% specific uptake, respectively; P < 0.0001). Conclusion: Our results confirm the potential of CR3022 as a molecularly targeted probe for SARS-CoV-2. A labeled version of CR3022 could potentially be used for Auger radiotherapy or noninvasive imaging.
【저자키워드】 COVID-19, SARS-CoV-2, Radiotherapy, auger, CR3022, 【초록키워드】 coronavirus, antibody, severe acute respiratory syndrome Coronavirus, Spike protein, SARS-CoV-2 spike protein, binding, noninvasive, CR3022, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, purity, selective, magnetic bead, probe, bind, specific activity, tested, significantly, reduced, absence, purified, yielding, 【제목키워드】 option,